Combination Therapy with Paroxetine and Bupropion
Combining paroxetine (Paxil) and bupropion (Wellbutrin) is generally safe and can be initiated together, but requires careful attention to drug interactions, particularly bupropion's inhibition of CYP2D6 which significantly increases paroxetine levels.
Key Drug Interaction Considerations
Bupropion is a potent CYP2D6 inhibitor that can substantially increase plasma concentrations of paroxetine 1. This interaction is clinically significant because:
- Paroxetine is metabolized primarily through CYP2D6
- Bupropion inhibits this enzyme, potentially increasing paroxetine exposure
- Similar interactions have been documented with other SSRIs metabolized by CYP2D6 2
Critical caveat: The combination of bupropion with paroxetine has been associated with severe bradycardia and atrioventricular block when used with beta-blockers like metoprolol, due to the compounded CYP2D6 inhibition 2, 3. Screen for concurrent cardiovascular medications before initiating.
Recommended Dosing Strategy
Starting Regimen
For treatment-naive patients or first-line therapy:
- Paroxetine: Start at 10 mg daily (morning or evening) 4, 5
- Bupropion: Start at 150 mg once daily in the morning 4, 1
- Increase bupropion to 150 mg twice daily after 3 days if tolerated 4
- Maximum bupropion dose: 300 mg/day (150 mg twice daily) 4, 1
For augmentation in partial responders:
- If patient is already on paroxetine monotherapy, add bupropion SR 150 mg/day initially
- Monitor closely for 1-2 weeks before increasing bupropion dose
- Consider that paroxetine levels may increase by 2-3 fold due to CYP2D6 inhibition 2
- May need to reduce paroxetine dose if side effects emerge after adding bupropion
Dose Titration
- Increase paroxetine by 10 mg increments every 5-7 days as tolerated 4
- Maximum paroxetine: 40 mg/day (standard); 50 mg/day (elderly/debilitated) 4, 5
- Bupropion second dose should be given before 3 PM to minimize insomnia 4
Clinical Evidence for Combination
The combination has demonstrated efficacy in two key scenarios:
1. Treatment-resistant depression: Open-label studies show 70-78% of partial responders to SSRI monotherapy improved with bupropion augmentation 6, 7, 8. One controlled trial found combination therapy from treatment initiation achieved faster remission (week 2: 18% vs 0% for monotherapies) 9.
2. SSRI-induced sexual dysfunction: Bupropion augmentation significantly improved sexual dysfunction, particularly orgasmic delay, in 78% of patients 6, 8.
Monitoring Requirements
Initial Assessment (Before Starting)
- Screen for seizure risk factors (stroke, brain metastases, eating disorders) - absolute contraindication to bupropion 10, 1
- Screen for bipolar disorder risk (detailed psychiatric and family history) 5
- Document concurrent medications, especially:
Ongoing Monitoring
- First 2 weeks: Monitor for serotonin syndrome symptoms (agitation, confusion, tremor, tachycardia, hyperthermia) 11, 5
- Weeks 2-4: Assess for emerging suicidality, agitation, or mood destabilization 5
- Week 4-8: Evaluate therapeutic response; full trial requires 4-8 weeks 4
- Monitor for common side effects:
Contraindications and Special Populations
Absolute contraindications:
- Concurrent MAOI use (14-day washout required) 5, 1
- Seizure disorder or conditions increasing seizure risk 10, 1
- Eating disorders (for bupropion) 10
- Concurrent thioridazine use (for paroxetine) 5
Elderly/debilitated patients:
- Start paroxetine at 12.5 mg/day (if using CR formulation) or 10 mg/day (immediate release) 5
- Use lower bupropion doses (37.5 mg initially, titrate slowly) 4
- Maximum paroxetine: 40 mg/day in elderly 5
Pregnancy considerations:
- Paroxetine has 2-3 fold increased risk of cardiac malformations (particularly VSDs) in first trimester 5
- Consider tapering paroxetine in third trimester due to neonatal complications 5
- Weigh risks vs benefits carefully; consider alternative SSRIs if pregnancy planned
Discontinuation Protocol
Never stop abruptly - both medications require gradual taper:
- Paroxetine: Taper over 10-14 days minimum to avoid discontinuation syndrome (dizziness, paresthesias, anxiety, GI symptoms) 4, 11, 5
- Bupropion: Can be discontinued more rapidly but gradual reduction preferred
- If discontinuing both, taper paroxetine first (higher discontinuation syndrome risk)
- Resume previous dose if intolerable symptoms emerge, then taper more gradually 5
Common Pitfalls to Avoid
- Starting both at full doses simultaneously - increases side effect burden and makes it difficult to identify which medication is causing problems
- Ignoring cardiovascular medication interactions - particularly dangerous with beta-blockers 2, 3
- Inadequate seizure risk screening - bupropion is absolutely contraindicated with seizure history 10
- Failing to warn about insomnia - give second bupropion dose before 3 PM 4
- Not monitoring for bipolar conversion - antidepressant combinations may precipitate mania in undiagnosed bipolar disorder 5